Home > Publications Database > Acute suppression of mitochondrial ATP production prevents apoptosis and provides an essential signal for NLRP3 inflammasome activation. > print

001     275933
005     20250126000518.0
024 7 _ |a 10.1016/j.immuni.2024.10.012
|2 doi
024 7 _ |a pmid:39571574
|2 pmid
024 7 _ |a 1074-7613
|2 ISSN
024 7 _ |a 1097-4180
|2 ISSN
024 7 _ |a altmetric:170890357
|2 altmetric
037 _ _ |a DZNE-2025-00155
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Saller, Benedikt S
|b 0
245 _ _ |a Acute suppression of mitochondrial ATP production prevents apoptosis and provides an essential signal for NLRP3 inflammasome activation.
260 _ _ |a [Cambridge, Mass.]
|c 2025
|b Cell Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1737366647_4999
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a How mitochondria reconcile roles in functionally divergent cell death pathways of apoptosis and NLRP3 inflammasome-mediated pyroptosis remains elusive, as is their precise role in NLRP3 activation and the evolutionarily conserved physiological function of NLRP3. Here, we have shown that when cells were challenged simultaneously, apoptosis was inhibited and NLRP3 activation prevailed. Apoptosis inhibition by structurally diverse NLRP3 activators, including nigericin, imiquimod, extracellular ATP, particles, and viruses, was not a consequence of inflammasome activation but rather of their effects on mitochondria. NLRP3 activators turned out as oxidative phosphorylation (OXPHOS) inhibitors, which we found to disrupt mitochondrial cristae architecture, leading to trapping of cytochrome c. Although this effect was alone not sufficient for NLRP3 activation, OXPHOS inhibitors became triggers of NLRP3 when combined with resiquimod or Yoda-1, suggesting that NLRP3 activation requires two simultaneous cellular signals, one of mitochondrial origin. Therefore, OXPHOS and apoptosis inhibition by NLRP3 activators provide stringency in cell death decisions.
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a ATP
|2 Other
650 _ 7 |a NLRP3
|2 Other
650 _ 7 |a OXPHOS
|2 Other
650 _ 7 |a apoptosis
|2 Other
650 _ 7 |a bioenergetics
|2 Other
650 _ 7 |a cell death
|2 Other
650 _ 7 |a chemical biology
|2 Other
650 _ 7 |a cytochrome c
|2 Other
650 _ 7 |a inflammasome
|2 Other
650 _ 7 |a mitochondria
|2 Other
650 _ 7 |a pyroptosis
|2 Other
650 _ 7 |a NLR Family, Pyrin Domain-Containing 3 Protein
|2 NLM Chemicals
650 _ 7 |a Inflammasomes
|2 NLM Chemicals
650 _ 7 |a Adenosine Triphosphate
|0 8L70Q75FXE
|2 NLM Chemicals
650 _ 7 |a Nlrp3 protein, mouse
|2 NLM Chemicals
650 _ 2 |a NLR Family, Pyrin Domain-Containing 3 Protein: metabolism
|2 MeSH
650 _ 2 |a Inflammasomes: metabolism
|2 MeSH
650 _ 2 |a Mitochondria: metabolism
|2 MeSH
650 _ 2 |a Apoptosis
|2 MeSH
650 _ 2 |a Adenosine Triphosphate: metabolism
|2 MeSH
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Oxidative Phosphorylation
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Signal Transduction
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Pyroptosis
|2 MeSH
700 1 _ |a Wöhrle, Svenja
|b 1
700 1 _ |a Fischer, Larissa
|0 P:(DE-2719)9002356
|b 2
|u dzne
700 1 _ |a Dufossez, Clara
|b 3
700 1 _ |a Ingerl, Isabella L
|b 4
700 1 _ |a Kessler, Susanne
|b 5
700 1 _ |a Mateo-Tortola, Maria
|b 6
700 1 _ |a Gorka, Oliver
|b 7
700 1 _ |a Lange, Felix
|b 8
700 1 _ |a Cheng, Yurong
|b 9
700 1 _ |a Neuwirt, Emilia
|b 10
700 1 _ |a Marada, Adinarayana
|b 11
700 1 _ |a Koentges, Christoph
|b 12
700 1 _ |a Urban, Chiara
|b 13
700 1 _ |a Aktories, Philipp
|b 14
700 1 _ |a Reuther, Peter
|b 15
700 1 _ |a Giese, Sebastian
|b 16
700 1 _ |a Kirschnek, Susanne
|b 17
700 1 _ |a Mayer, Carolin
|b 18
700 1 _ |a Pilic, Johannes
|b 19
700 1 _ |a Falquez-Medina, Hugo
|b 20
700 1 _ |a Oelgeklaus, Aline
|b 21
700 1 _ |a Deepagan, Veerasikku Gopal
|b 22
700 1 _ |a Shojaee, Farzaneh
|b 23
700 1 _ |a Zimmermann, Julia A
|b 24
700 1 _ |a Weber, Damian
|b 25
700 1 _ |a Tai, Yi-Heng
|b 26
700 1 _ |a Crois, Anna
|b 27
700 1 _ |a Ciminski, Kevin
|b 28
700 1 _ |a Peyronnet, Remi
|b 29
700 1 _ |a Brandenburg, Katharina S
|b 30
700 1 _ |a Wu, Gang
|b 31
700 1 _ |a Baumeister, Ralf
|b 32
700 1 _ |a Heimbucher, Thomas
|b 33
700 1 _ |a Rizzi, Marta
|b 34
700 1 _ |a Riedel, Dietmar
|b 35
700 1 _ |a Helmstädter, Martin
|b 36
700 1 _ |a Buescher, Joerg
|b 37
700 1 _ |a Neumann, Konstantin
|b 38
700 1 _ |a Misgeld, Thomas
|0 P:(DE-2719)2810727
|b 39
|u dzne
700 1 _ |a Kerschensteiner, Martin
|b 40
700 1 _ |a Walentek, Peter
|b 41
700 1 _ |a Kreutz, Clemens
|b 42
700 1 _ |a Maurer, Ulrich
|b 43
700 1 _ |a Rambold, Angelika S
|b 44
700 1 _ |a Vince, James E
|b 45
700 1 _ |a Edlich, Frank
|b 46
700 1 _ |a Malli, Roland
|b 47
700 1 _ |a Häcker, Georg
|b 48
700 1 _ |a Kierdorf, Katrin
|b 49
700 1 _ |a Meisinger, Chris
|b 50
700 1 _ |a Köttgen, Anna
|b 51
700 1 _ |a Jakobs, Stefan
|b 52
700 1 _ |a Weber, Alexander N R
|b 53
700 1 _ |a Schwemmle, Martin
|b 54
700 1 _ |a Groß, Christina J
|b 55
700 1 _ |a Groß, Olaf
|b 56
773 _ _ |a 10.1016/j.immuni.2024.10.012
|g Vol. 58, no. 1, p. 90 - 107.e11
|0 PERI:(DE-600)2001966-X
|n 1
|p 90 - 107.e11
|t Immunity
|v 58
|y 2025
|x 1074-7613
856 4 _ |u https://pub.dzne.de/record/275933/files/DZNE-2025-00155%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/275933/files/DZNE-2025-00155.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/275933/files/DZNE-2025-00155.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:275933
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 2
|6 P:(DE-2719)9002356
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 39
|6 P:(DE-2719)2810727
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-01
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b IMMUNITY : 2022
|d 2025-01-01
915 _ _ |a IF >= 30
|0 StatID:(DE-HGF)9930
|2 StatID
|b IMMUNITY : 2022
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-01
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-01
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-01
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2025-01-01
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-01
920 1 _ |0 I:(DE-2719)1110000-4
|k AG Misgeld
|l Neuronal Cell Biology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1110000-4
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21